NASDAQ:CDTX - Cidara Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cidara Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.60 -0.04 (-1.52 %) (As of 12/13/2019 11:49 AM ET) Add Compare Today's Range$2.60Now: $2.60▼$2.6450-Day Range$1.85MA: $2.32▼$2.7252-Week Range$1.22Now: $2.60▼$3.30Volume2,500 shsAverage Volume210,095 shsMarket Capitalization$85.90 millionP/E RatioN/ADividend YieldN/ABeta2.14 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDTX Previous Symbol CUSIPN/A CIK1610618 Webhttp://www.cidara.com/ Phone858-752-6170Debt Debt-to-Equity Ratio0.02 Current Ratio2.45 Quick Ratio2.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book1.22Profitability EPS (Most Recent Fiscal Year)($2.32) Net Income$-59,020,000.00 Net MarginsN/A Return on Equity-85.79% Return on Assets-56.94%Miscellaneous Employees68 Outstanding Shares33,040,000Market Cap$85.90 million Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive CDTX News and Ratings via Email Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CDTX Rates by TradingView Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions What is Cidara Therapeutics' stock symbol? Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX." How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics Inc (NASDAQ:CDTX) posted its earnings results on Thursday, November, 7th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.26) by $0.34. The biotechnology company earned $19.10 million during the quarter, compared to the consensus estimate of $30 million. View Cidara Therapeutics' Earnings History. When is Cidara Therapeutics' next earnings date? Cidara Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Cidara Therapeutics. What price target have analysts set for CDTX? 6 equities research analysts have issued 1 year price targets for Cidara Therapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they anticipate Cidara Therapeutics' share price to reach $6.88 in the next twelve months. This suggests a possible upside of 164.4% from the stock's current price. View Analyst Price Targets for Cidara Therapeutics. What is the consensus analysts' recommendation for Cidara Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cidara Therapeutics. What are Wall Street analysts saying about Cidara Therapeutics stock? Here are some recent quotes from research analysts about Cidara Therapeutics stock: 1. According to Zacks Investment Research, "Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California. " (8/21/2019) 2. Cantor Fitzgerald analysts commented, "CDTX’s pipeline is focused on better ways to treat fungal and bacterial infections as well as influenza. We expect pipeline advancements to drive upwards earnings revisions to levels not yet reflected in the consensus. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $15." (4/15/2019) Has Cidara Therapeutics been receiving favorable news coverage? Headlines about CDTX stock have trended positive on Friday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cidara Therapeutics earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Cidara Therapeutics. Who are some of Cidara Therapeutics' key competitors? Some companies that are related to Cidara Therapeutics include Cellular Biomedicine Group (CBMG), Eiger Biopharmaceuticals (EIGR), Jounce Therapeutics (JNCE), CASI Pharmaceuticals (CASI), Scholar Rock (SRRK), Compugen (CGEN), Sutro Biopharma (STRO), ADMA Biologics (ADMA), Aptose Biosciences (APTO), Cabaletta Bio (CABA), Solid Biosciences (SLDB), Nantkwest (NK), LogicBio Therapeutics (LOGC), Dyadic International (DYAI) and Windtree Therapeutics (WINT). What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Zynerba Pharmaceuticals (ZYNE), SCYNEXIS (SCYX), Nektar Therapeutics (NKTR), Viking Therapeutics (VKTX), Anavex Life Sciences (AVXL), Exelixis (EXEL) and TherapeuticsMD (TXMD). Who are Cidara Therapeutics' key executives? Cidara Therapeutics' management team includes the folowing people: Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 64)Dr. Taylor Sandison, Chief Medical Officer (Age 47)Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 42)Mr. James E. Levine, Chief Financial Officer (Age 48)Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 50) When did Cidara Therapeutics IPO? (CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. Who are Cidara Therapeutics' major shareholders? Cidara Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Granahan Investment Management Inc. MA (1.40%). Company insiders that own Cidara Therapeutics stock include James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian and Paul Daruwala. View Institutional Ownership Trends for Cidara Therapeutics. Which major investors are buying Cidara Therapeutics stock? CDTX stock was bought by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA. Company insiders that have bought Cidara Therapeutics stock in the last two years include James E Levine and Jeffrey Stein. View Insider Buying and Selling for Cidara Therapeutics. How do I buy shares of Cidara Therapeutics? Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Cidara Therapeutics' stock price today? One share of CDTX stock can currently be purchased for approximately $2.60. How big of a company is Cidara Therapeutics? Cidara Therapeutics has a market capitalization of $85.90 million. The biotechnology company earns $-59,020,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe.View Additional Information About Cidara Therapeutics. What is Cidara Therapeutics' official website? The official website for Cidara Therapeutics is http://www.cidara.com/. How can I contact Cidara Therapeutics? Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected] MarketBeat Community Rating for Cidara Therapeutics (NASDAQ CDTX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 351 (Vote Outperform)Underperform Votes: 261 (Vote Underperform)Total Votes: 612MarketBeat's community ratings are surveys of what our community members think about Cidara Therapeutics and other stocks. Vote "Outperform" if you believe CDTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2019 by MarketBeat.com StaffFeatured Article: Why are gap-down stocks important?
